BioMarin Pharmaceutical (NASDAQ: BMRN) net income
BioMarin Pharmaceutical reported a net profit of $348.9m for fiscal 2025, 18.3% less than in fiscal 2024 ($426.9m). Its net margin was 10.8%. Earnings per share were $1.82.
BioMarin Pharmaceutical's best year of the last 10 was fiscal 2020. The biggest drop was in fiscal 2025, −18.3%. It reported a loss in 5 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | $348.9m | −18.3% | 10.8% | $1.82 |
| 2024 | $426.9m | +154.6% | 15.0% | $2.25 |
| 2023 | $167.6m | +18.4% | 6.9% | $0.89 |
| 2022 | $141.6m | — | 6.8% | $0.76 |
| 2021 | −$64.1m | −107.5% | −3.5% | −$0.35 |
| 2020 | $854.0m | — | 45.9% | $4.75 |
| 2019 | −$23.8m | — | −1.4% | −$0.13 |
| 2018 | −$77.2m | — | −5.2% | −$0.44 |
| 2017 | −$117.0m | — | −8.9% | −$0.67 |
| 2016 | −$630.2m | — | −56.4% | −$3.80 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
BioMarin Pharmaceutical net income compared with its sector
By net income for its latest fiscal year, BioMarin Pharmaceutical ranks 71st of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of BioMarin Pharmaceutical, 10.8%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 69th | Cooper Companies | $374.9m | 9.2% |
| 70th | Rigel Pharmaceuticals | $367.0m | 124.7% |
| 71st | BioMarin Pharmaceutical | $348.9m | 10.8% |
| 72nd | Ensign Group | $344.0m | 6.8% |
| 73rd | Halozyme Therapeutics | $316.9m | 22.7% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of BioMarin Pharmaceutical
- How much did BioMarin Pharmaceutical earn in fiscal 2025?
- BioMarin Pharmaceutical reported a net profit of $348.9m for fiscal 2025. In fiscal 2024 it reported a net profit of $426.9m.
- What are the earnings per share of BioMarin Pharmaceutical?
- They were $1.82 in fiscal 2025, compared with $2.25 in fiscal 2024.
- What is the net margin of BioMarin Pharmaceutical?
- In fiscal 2025 its net profit was 10.8% of its revenue.
- What was the most profitable year for BioMarin Pharmaceutical?
- Of its last 10 fiscal years, fiscal 2020, with $854.0m.
- Where does BioMarin Pharmaceutical rank in its sector by net income?
- It ranks 71st of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for BioMarin Pharmaceutical come from?
- From the annual report (Form 10-K) that BioMarin Pharmaceutical files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that BioMarin Pharmaceutical files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on BioMarin Pharmaceutical: the BioMarin Pharmaceutical page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.